Neural patterns predicted which participants classified as high or low performers based on attention networks during the game. LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive ...

LOS ANGELES--(BUSINESS WIRE)-- Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular ...

Please provide your email address to receive an email when new articles are posted on . Neurotechnology firm Kernel and biopharmaceutical company Cybin announced promising pilot results from a ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of ...

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced key highlights from the completed ...

At last year's SPIE Photonics West, California-based neurotech start-up Kernel revealed the system architecture of its proposed Kernel Flux optically-pumped magnetometer platform designed to record ...

New feasibility study indicates that VR has the potential to drive physiological changes in the body and brain associated with pain relief LOS ANGELES, Feb. 8, 2024 /PRNewswire/ -- AppliedVR ®, a ...

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway, announced Cybin Inc. CYBN, which is sponsoring the research that will make heavy use ...

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced that the first study visit has ...